Navigation Links
Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration

BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.

The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.

"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship."

Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts."

Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation and development problems. Bend Research prides itself in offering fast, innovative solutions.

Since late 2008, Bend Research has been rapidly expanding its line-up of industrial partners. Customers that have benefitted from Bend Research's proprietary technology and unique formulation expertise include some two dozen major pharmaceutical companies, mid-size pharmas, and biotech companies around the globe.

About Bend Research Inc.

Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies. The firm develops innovative drug-delivery solutions from a solid base of fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.

The company's flexible, client-focused business model and collaborative approach to working with its customers enable long-term alliances with clients focused on value creation.

Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small-molecule drugs for serious diseases. The company's strategy is to commercialize products independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.


    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701

    Phone: +1(541)-382-4100
    Fax: +1(541)-382-2713

SOURCE Bend Research Inc.

SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology:
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one ... , Their study showed that small molecule analogs that target the functions of ...
(Date:11/30/2015)... ... 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics and is ... Margulies to experience the best available orthodontic experience in the area. Dr. Margulies ... , Orthodontics is the branch of dentistry that specializes in the diagnosis, prevention, and ...
Breaking Medicine News(10 mins):